# Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer

> **NCT05830279** · — · RECRUITING · sponsor: **London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's** · enrollment: 600 (estimated)

## Conditions studied

- Nausea With Vomiting Chemotherapy-Induced
- Depression, Reactive
- Cancer Pain

## Interventions

- **GENETIC:** Pharmacogenetic testing
- **OTHER:** Drug-Drug interaction analysis

## Key facts

- **NCT ID:** NCT05830279
- **Lead sponsor:** London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-01
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05830279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05830279, "Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05830279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*